Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

252
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
252
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

6.6K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.6K
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

37
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
37
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LLM-Driven Extraction of NI-RADS and Imaging Tumor Characteristics to Enhance Oropharyngeal Cancer Survivorship Surveillance.

medRxiv : the preprint server for health sciences·2026
Same author

Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study.

Cancer letters·2026
Same author

Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same author

Sex differences in nerve injury-induced neuropathic pain via REST in primary sensory neurons.

Neurobiology of pain (Cambridge, Mass.)·2026

Related Experiment Video

Updated: Jun 24, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

494

REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors.

Cheng-Han Yang1, Evan Kwiatkowski1, J Jack Lee2

  • 1Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

Statistics in Medicine
|June 10, 2024
PubMed
Summary
This summary is machine-generated.

Identifying the optimal biological dose (OBD) for precision cancer treatments is crucial. A new Bayesian meta-analysis (REDOMA) method synthesizes data from multiple trials to accurately determine the OBD, considering both toxicity and efficacy.

Keywords:
Bayesian methodsdose optimizationmeta‐analysisphase I/II trialspike‐and‐slab prior

More Related Videos

Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI
06:26

Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI

Published on: November 27, 2019

70.6K
A Simple Stimulatory Device for Evoking Point-like Tactile Stimuli: A Searchlight for LFP to Spike Transitions
07:34

A Simple Stimulatory Device for Evoking Point-like Tactile Stimuli: A Searchlight for LFP to Spike Transitions

Published on: March 25, 2014

9.9K

Related Experiment Videos

Last Updated: Jun 24, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

494
Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI
06:26

Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI

Published on: November 27, 2019

70.6K
A Simple Stimulatory Device for Evoking Point-like Tactile Stimuli: A Searchlight for LFP to Spike Transitions
07:34

A Simple Stimulatory Device for Evoking Point-like Tactile Stimuli: A Searchlight for LFP to Spike Transitions

Published on: March 25, 2014

9.9K

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Precision cancer treatments necessitate determining the optimal biological dose (OBD).
  • Traditional methods assume a monotone dose-efficacy relationship, which may not apply to novel therapies.
  • Identifying OBD reliably from single small-sample trials is challenging.

Purpose of the Study:

  • To propose a novel Bayesian random-effects dose-optimization meta-analysis (REDOMA) approach.
  • To accurately identify the OBD by synthesizing toxicity and efficacy data from multiple trials.
  • To address heterogeneous trial characteristics in dose-optimization.

Main Methods:

  • Utilized a Bayesian random-effects meta-analysis framework (REDOMA).
  • Employed a curve-free approach with a Gamma process prior for dose-toxicity modeling.
  • Applied Bayesian model selection with spike-and-slab priors to relax monotonic dose-efficacy constraints.

Main Results:

  • The REDOMA method effectively synthesizes toxicity and efficacy data across heterogeneous trials.
  • Demonstrated the ability to identify the OBD without assuming monotonic dose-efficacy relationships.
  • Extensive simulation studies confirmed the method's robust performance.

Conclusions:

  • The REDOMA approach offers a powerful tool for optimal biological dose determination in oncology.
  • This method enhances the accuracy of identifying OBD for novel precision cancer therapies.
  • REDOMA facilitates more reliable dose optimization by integrating data from multiple early-phase trials.